Chemomab Therapeutics reported Q1 2026 financial results showing a net loss of $1.8 million and cash position of $8.0 million (runway through Q1 2027). The company presented new clinical data at major medical conferences demonstrating nebokitug's disease-modifying potential in primary sclerosing cholangitis (PSC) and...
Chemomab Therapeutics reported positive 2025 results highlighted by successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), establishing a clear pathway to potential regulatory approval based on a single Phase 3 trial. The company's Phase 2 SPRING trial data showed nebokitug was...
Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.
Chemomab Therapeutics reported positive Phase 2 results for its lead drug candidate CM-101 in primary sclerosing cholangitis, demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company plans to advance CM-101 to a Phase 3 trial and is in discussions with potential partners.
Chemomab Therapeutics, a clinical-stage biotechnology company, announced it will report its Q2 2024 financial results and provide a business update on August 21, 2024. The company is developing a monoclonal antibody, CM-101, to treat various fibro-inflammatory diseases.
Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference...
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion. M.D.C. shares surged 17.4% to...
After losing some value lately, a hammer chart pattern has been formed for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Shares of The Children's Place, Inc. (NASDAQ: PLCE) moved lower during Thursday’s session following weak quarterly earnings. Children's Place posted adjusted earnings of $3.22 per share, missing market estimates of $3.56 per share. The company’s quarterly sales came in at $480.23 million versus estimates of $471.82...
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. Palo Alto Networks reported quarterly earnings of $1.38 per share, above the analyst consensus estimate of $1.16. Revenue of $1.88 billion beat the analyst consensus estimate of $1.84 billion. Billings...
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 150 points on Wednesday. The Dow traded up 0.46% to 34,989.30 while the NASDAQ rose 0.16% to 14,116.28. The S&P 500 also rose, gaining, 0.26% to 4,507.40. Check This Out: Top 4 Energy Stocks That Are Preparing To Pump This...
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company’s quarterly sales came in at $8.37 million versus estimates of $8.75...
U.S. stocks traded higher this morning, with the Dow Jones gaining around 90 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.27% to 34,922.07 while the NASDAQ rose 0.36% to 14,144.63. The S&P 500 also rose, gaining, 0.27% to 4,507.75. Check This Out: Top 4 Energy Stocks That Are...
Upgrades According to B of A Securities, the prior rating for Clearway Energy Inc (NYSE:CWEN) was changed from Neutral to Buy. In the second quarter, Clearway Energy showed an EPS of $0.33, compared to $4.37 from the year-ago quarter. The stock has a 52-week-high of $36.54 and a 52-week-low of $18.59. At the end of the...
Headlines via Polygon.io. Links open the original publisher.